| "Patients with liver cancer were treated with adriamycin." | ( Olweny, CL, 1978) |
| "Seventeen patients with primary liver cancer were also treated with adriamycin." | ( Falkson, G; Falkson, HC; van der Merwe, AM; van Dyk, JJ, 1976) |
| "Ten patients with unresectable primary liver cancer, eight of whom had elevated serum alpha-fetoprotein levels, were treated with intrahepatic fluorodeoxyuridine (FUDR) and mitomycin C administered through an implantable pump." | ( Atiq, OT; Botet, J; Kemeny, N; Niedzwiecki, D, 1992) |
| "Forty patients with unresectable liver cancer were treated by hepatic arterial infusion chemotherapy plus embolization (HAI+HAE)." | ( Wang, JH, 1992) |
| "We reported a case of metastatic liver cancer from rectal carcinoma, which was successfully treated by systemic continuous 5-Fluorouracil and intermittent Mitomycin C chemotherapy." | ( Noguchi, S; Shibata, N, 1992) |
| "The risk of americium-induced liver cancer in beagle dogs that received long-term dietary ethanol was two to three times that of their nonalcoholic cohorts, even though the radionuclide retention time in hepatic tissue was shortened by the alcohol treatment." | ( Lloyd, RD; Mays, CW; Miller, SC; Shabestari, L; Taylor, GN, 1992) |
| "Four patients with metastatic liver cancer were treated with Yttrium-90 to deliver radiation doses above that considered tolerable when given by conventional external sources." | ( Burton, MA; Gray, BN; Kelleher, D; Klemp, P; Matz, L, 1990) |
| "In the treatment of metastatic liver cancer, arterial chemotherapy and transarterial embolization are the major modality." | ( Abe, M; Hirai, K; Kubo, Y; Majima, Y, 1987) |
| "Six cases of unresectable hepatic cancer in infant were treated with intra-arterial infusion therapy." | ( Abe, T; Hamada, H; Hata, Y; Saito, H; Sasaki, F; Sato, N; Sawada, H; Tamura, M; Uchino, J; Une, Y, 1989) |
| "Seven cases of liver cancer with replaced right hepatic artery were treated with arterial infusion therapy using implanted reservoir." | ( Gondo, H; Ishimura, M; Kamiyama, T; Matsuoka, S; Misawa, K; Nagabuchi, E; Nakajima, Y; Ogasawara, K; Tamura, M; Une, Y, 1989) |
| "In the patients with metastatic liver cancer, tumor regression over 50% was observed in 65% of the patients treated with chemoembolization alone and in 33% of those with chemoembolization and HT." | ( Itani, K; Kondo, M; Oyamada, H; Seto, O; Sugino, S; Tainaka, K; Yoshikawa, T, 1988) |
| "No increase in incidence of liver neoplasms was observed after treatment with any of the four compounds, thenyldiamine, chlorothen, methafurylene, or methaphenilene, although each differed structurally from methapyrilene only in one atom or one position of substitution." | ( Kovatch, RM; Lijinsky, W, 1986) |
| "Four hepatocellular cancer patients and 11 metastatic liver cancer patients were treated with intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) plus 5-fluorouracil." | ( Koga, S; Maeta, M; Murakami, A; Wakatsuki, T; Yoshioka, H, 1985) |
| "The MMC MS treatment for metastatic hepatic cancer had superiority to the conventional infusion treatment at p = 0." | ( Endoh, F, 1987) |
| "Forty-seven patients with hepatocellular cancer were treated in a randomised trial comparing adriamycin + VM 26 + 5-Fluorouracil (5-FU) to mAMSA + VM 26 + 5-FU." | ( Bezwoda, WR; Derman, DP; Kew, M; Weaving, A, 1987) |
| "Three patients with primary liver cancer were treated with DSM (600-1200 mg) and ADR (20-60 mg), and five with metastatic liver cancer were treated with DSM and MMC (10-20 mg)." | ( Fujita, M; Nakamura, H; Ota, J; Taguchi, T, 1988) |
| "Eight hepatocellular cancer patients and eighteen metastatic liver cancer patients were treated with intrahepato-arterial infusion of CDDP (cis-diamminedichloro-platinum II) plus 5-FU (5-fluorouracil); CDDP (0." | ( Ikeda, Y; Inoue, Y; Ishiguro, M; Koga, S; Maeta, M; Wakatsuki, T, 1987) |
| "Of the 118 patients with primary liver cancer treated in our clinic during a 6 year 7 month period, 11 patients had cholangiocellular carcinoma of the liver." | ( Kawarada, Y; Mizumoto, R, 1984) |
| "Since 1977 multiple primary liver cancers including AGS developed in thorotrast-administered patients in both groups." | ( Hosoda, S; Kido, C; Takahashi, S; Tateno, H; Yamada, S, 1983) |
| "Twenty liver cancer patients, including 9 hepatocellular carcinoma and 11 with metastatic liver cancer, were treated by intra-arteral one-shot chemotherapy." | ( Fujii, H; Katake, K; Miyoshi, M; Nishimura, S; Nishitani, T; Seki, S; Suyama, Y; Tada, M; Tanaka, Y, 1983) |
| "To study the effectiveness of CDDP for hepatic cancer, intra-hepato-arterial administration of CDDP (0." | ( Hirooka, Y; Kanayama, H; Koga, S; Maeta, M; Murakami, A; Oda, M; Osaki, Y, 1984) |
| "To prevent probable occult metastatic liver cancer from progressing to clinical disease, the author used internal radiation therapy as an effective adjuvant to surgical excision of primary Dukes' C colonic cancer." | ( Grady, ED, 1984) |
| "Ascitic fluid of patients with primary liver cancer was shown to contain a latent thiol proteinase which can be activated by pepsin treatment or by autolysis at acidic environment." | ( Bures, L; Dufek, V; Král, V; Matous, B, 1984) |
| "The incidence of liver neoplasms in the rats given pyrilamine in the drinking-water did not differ from that in the untreated controls, of which five males and three females had neoplastic nodules in the liver." | ( Lijinsky, W, 1984) |
| "The incidence of liver neoplasms, which were carcinomas and neoplastic nodules, in the two groups of females treated with sodium nitrite in feed was significantly higher than in the controls, but there was no significant difference in the males." | ( Kovatch, R; Lijinsky, W; Riggs, CW, 1983) |
| "Sixteen patients were treated for liver cancer (primary and metastatic) by a combination of internal radiation therapy with intra-arterial yttrium 90 microspheres and regional hyperthermia with electromagnetic radiation." | ( Auda, SP; Grady, ED; McGinley, PH; McLaren, J, 1983) |
| "Patients with unresectable liver cancer (primary and metastatic) were treated with a newly-devised arterial infusion chemotherapy using Cis-DDP and its antidote Sodium thiosulfate (STS)." | ( Abe, R; Akiyoshi, T; Arinaga, S; Asoh, T; Baba, T; Koba, F; Miyazaki, S; Shirasaka, C; Takeuchi, Y; Tsuii, H; Uchida, I; Wada, T, 1983) |
| "Eighteen patients with nonresectable liver cancer were treated by dearterialization of the liver." | ( Inokuchi, K; Nagasue, N, 1982) |
| "Ninety-four patients with primary liver cancer have been treated with electrochemical therapy (ECT) in our hospital." | ( Wang, HL, 1994) |
| "Fischer 344 rats readily develop liver cancer when exposed to aflatoxin B1 (AFB1) but dietary administration of the antioxidant ethoxyquin (EQ) provides protection against hepatocarcinogenesis." | ( Hayes, JD; Judah, DJ; Neal, GE, 1993) |
| "The clinical therapy in six liver cancer patients was successful." | ( Pu, YL; Shi, TS; Wang, YM; Zhao, YL; Zhu, JG, 1995) |
| "Similarly, when CBRH-7919 rat liver cancer cells were treated with phorbol 12-myristate 13-acetate, a proliferation stimulator of the cells, gamma-GT and Ca2+-dependent activities of PC-PLC and the expression of alpha-fetoprotein increased significantly." | ( Chen, H; Huang, Y; Lu, H; Wu, X; Zhou, L, 1997) |
| "Primary liver cancer is a significant health problem; treatment options are limited and prognosis is poor." | ( Evers, BM; Li, J; Wang, X; Wang, XM, 1998) |
| "Human liver cancer cell lines HepG2 and Hep3B were treated with 5-azaC alone, butyrate alone, or 5-azaC and butyrate." | ( Evers, BM; Li, J; Wang, X; Wang, XM, 1998) |
| "Many cases with metastatic hepatic cancer have a poor prognosis because of the appearance of extrahepatic lesions in spite of the fact that a partial response can be obtained by hepatic arterial infusion chemotherapy." | ( Hasegawa, K; Ichikawa, T; Kawai, S; Kirihara, M; Kume, S; Maruo, H; Tominaga, S, 1998) |
| "Patients with unresectable liver cancer treated with intra-arterial doxorubicin lived no longer than untreated controls (median 8 months (range 1-56) compared with 7 months (range 1-28))." | ( Hafström, L; Holmberg, S; Lindnér, P; Naredi, P; Scherstén, T, 1998) |
| "Treatment of patients with primary liver cancer is still an unsolved problem." | ( Hafström, L; Holmberg, S; Lindnér, P; Naredi, P; Scherstén, T, 1998) |
| "The most frequent form of primary liver cancer is hepatocellular carcinoma, which is essentially refractory to chemotherapy." | ( Diaconu, CC; Kéri, G; Szathmári, M; Venetianer, A, 1999) |
| "A novel strategy for immune therapy of liver neoplasms with the use of redox-modulating agents has been proposed." | ( Inamoto, T; Tsuyuki, S; Yamaoka, Y; Yamauchi, A, 1999) |
| "Seventeen patients with liver cancer were treated with glass microspheres from August 1996 to May 1998." | ( Cao, X; He, N; Li, J; Lu, T; Sun, J; Tan, J; Yang, J; Zhang, C, 1999) |
| "Twenty-nine advanced primary liver cancer and 4 gallbladder cancer patients were treated with As2O3 injection only, 15 mg i." | ( He, Z; Qian, J; Qin, S, 2001) |
| "For most patients with primary liver cancer surgical treatment is not feasible and prognosis without treatment is poor." | ( Achenbach, T; Junginger, T; Pitton, MB; Schunk, K; Seifert, JK, 2002) |
| "These results suggest that (1) intrahepatic cancer responds to 5FC when cells express yCD; (2) the luciferin-luciferase system permits non-invasive real time imaging of viable intrahepatic cancer; and (3) this system can be used to carry out gene therapy experiments using yCD adenovirus." | ( Dornfeld, KJ; Kievit, E; Lawrence, TS; Nyati, MK; Rehemtulla, A; Ross, BD; Rynkiewicz, SD; Symon, Z, 2002) |
| "This case suggested that even if a huge liver cancer with vascular invasion is judged impossible to excise, multimodal therapy with the aim of surgical treatment helps retain the possibility to later chose hepatectomy for the primary lesion and improve prognosis." | ( Beppu, T; Doi, K; Hirota, M; Ishiko, T; Ogawa, M, 2002) |
| "Transarterial therapy for primary liver cancer is gaining more acceptance." | ( Kim, P; Prapong, W; Razavi, MK; So, SK; Sze, DY, 2002) |
| "In 5 patients with metastases of liver cancer in retroperitoneal lymph nodes who received 1 to 3 times of PEI, all the foci treated were completely necrotic and smaller demonstrated by dynamic contrast-enhanced CT or MRI 3 months later." | ( Hao, XY; Ren, FY; Shao, CW; Tian, JM; Wang, MJ; Wang, PJ; Xiao, Y; Yuan, M; Zuo, CJ, 2004) |
| "The observed excess mortality from liver cancer is compatible, to some extent, with exposures that may have occurred during the manufacture of phenolic and furfuryl resins treated products, although a role of lifestyle factors and viral infections cannot be excluded." | ( Ceppi, M; Covolo, L; Donato, F; Garattini, S; Gelatti, U; Merlo, DF; Simonati, C, 2004) |
| "65 patients with advance stage of liver cancer were randomly into two groups, the control group (regular protective therapy) and the treatment group (regular protective therapy + JWSJZT)." | ( Chen, X; Hu, P; Huang, G; Xu, B; Zhang, B; Zhang, Y, 2004) |
| "Survival correlated with pretreatment Cancer of the Liver Italian Program scores ( P = ." | ( Carr, BI; Geschwind, JF; Goin, JE; Goin, KA; Roberts, CA; Salem, R; Soulen, MC; Thurston, KG; Van Buskirk, M, 2004) |
| "Forty-nine patients with liver cancer were retrospectively divided into two groups: Treatment group, on the basis of TACE, 23 patients received oral capecitabine at 2500 mg/m(2), twice-daily for 14 days followed by 7-day rest period and repeated in every three week intervals for more than two cycles." | ( Chen, AJ; Hu, MD; Li, L; Li, XY; Ran, JH; Sun, F; Tang, JH, 2004) |
| "Thirty patients with 38 lesions of liver cancer were treated by the CT mediated intratumor injection of HAS6." | ( Hongmei, Z; Lei, Z; Ni, J; Suhong, H; Weijian, F; Yanjie, Z; Yi, C; Zan, L, 2006) |
| "In rat liver cancer, a functional sodium iodide symporter expression was triggered as from the early preneoplastic steps, and was amplified during clonal tumor cell expansion, allowing complete tumor suppression after (131)I radiotherapy." | ( Bioulac-Sage, P; Boisgard, R; Bréchot, C; Calès, P; Clerc, J; Faivre, J; Guettier, C; Hervé, J; Liu, B; Roux, J; Samuel, D; Tavitian, B; Valogne, Y; Yilmaz, F, 2007) |
| "Primary and secondary liver cancer have longtime been characterized by an overall poor prognosis since the majority of patients are not candidates for surgical resection with curative intent, systemic chemotherapy alone has rarely resulted in long-term survival, and the role of conventional external beam radiation therapy has traditionally been limited due to the relative sensitivity of the liver parenchyma to radiation." | ( Hobbelink, MG; Nijsen, JF; van Het Schip, AD; Vente, MA; Zonnenberg, BA, 2007) |
| "The increased risk of primary liver cancer in ursodeoxycholic acid-treated patients was 3-fold (HR, 3." | ( Aithal, GP; Card, TR; Jackson, H; Logan, R; Solaymani-Dodaran, M; West, J, 2007) |
| "Patients with intrahepatic cancer undergoing conformal radiotherapy underwent dynamic contrast-enhanced computed tomography (to measure perfusion distribution) and an indocyanine extraction study (to measure liver function) before, during, and 1 month after treatment." | ( Balter, JM; Ben-Josef, E; Cao, Y; Francis, IR; Knol, JA; Lawrence, TS; Normolle, D; Pan, C; Platt, JF; Ten Haken, RK, 2008) |
| "Fifty primary liver cancer patients were randomly divided into two groups: therapeutic and control group, and all were treated with transfemoral artery chemoembolization (TACE) with oxaliplatin 150 mg, pharmorubicin 50 mg, 5-Fu 750 mg, CF 300 mg and lipiodol 20 ml." | ( Li, T; Li, ZW; Wen, HC, 2007) |
| "Advanced hepatocellular cancer (HCC) is a highly vascularised tumor with limited treatment options." | ( Malfertheiner, P; Treiber, G; Wex, T, 2009) |
| "Patients with primary or secondary liver cancer who are not suitable for surgical resection may be treated with selective internal radiation therapy with yttrium-90." | ( Bester, L; Chernyak, I; Freund, J; Richardson, M, 2008) |
| "Human liver cancer line 7402 was treated by Tet and Nap in various concentrations respectively or in combination in vitro,and then the cell growth was assayed by MTT method, periodic return changes were observed by aridine orange (AO)-/ethidiumbromide (EB) fluorescent staining, DNA gel eledtophoresis and flow cytometry, and the expression of apoptosis-related genes were analyzed by immunohistochemical staining method." | ( Chen, XB; Deng, WY; Han, LL; Li, N; Luo, SX; Zhou, MQ, 2008) |
| "In patients with unresectable primary liver cancer, HAI therapy can be effective and safe." | ( Blumgart, LH; D'Angelica, M; DeMatteo, R; Fong, Y; Gönen, M; Gultekin, DH; Haviland, D; Jarnagin, WR; Kemeny, N; Schwartz, LH; Shia, J; Tse, A, 2009) |
| "Conventional chemotherapy of liver cancer fails to provide satisfactory remission and may cause serious side effects, thus it is crucial to derive alternative treatments that effectively inhibit cancer cell growth with known mechanisms of action." | ( Auyeung, KK; Ko, JK, 2009) |
| "In summary, human liver cancer cells treated with chrysophanol exhibited a cellular pattern associated with necrosis and not apoptosis." | ( Chou, ST; Chung, JG; Hsia, TC; Huang, AC; Kuo, CL; Lee, TH; Lu, CC; Lu, HF; Wood, WG; Yang, JS, 2010) |
| "CD133+ liver cancer cells are characterized by resistance to chemotherapy, self-renewal, multilineage potential, increased colony formation, and in vivo cancer initiation at limited dilution." | ( Ding, W; Rountree, CB; You, H, 2010) |
| "Treatment options for advanced hepatocellular cancer (HCC) are limited." | ( Dawson, LA; Horgan, AM; Knox, JJ; Swaminath, A, 2012) |
| "Twenty-eight patients with liver cancer were treated with Nexavar." | ( Kan, HP; Tan, YF; Wang, Y; Zhou, J, 2010) |
| "Because only 20% of hepatic cancers are operable in patients, several types of regional therapy (RT) are emerging as alternate treatment modalities." | ( Alcala, MA; Bartlett, DL; Kwan, SY; Lang, M; Lee, YJ; Petoud, S; Shade, CM; Uh, H; Wang, M; Weber, SG, 2011) |
| "The relative resistance of liver cancer cells to ionizing radiation (IR) and chemotherapeutic agents due to autophagic response limits the available treatment options for this type of cancer." | ( Chiang, HC; Chou, FP; Kuo, WH; Liu, WS; Tseng, HC; Tyan, YS, 2011) |
| "Seventy five patients with liver cancer adjacent to major blood vessels were randomly divided into two groups: PRFA+PEI therapy group (38 cases) and PRFA control group (37 cases)." | ( Du, JD; Jiao, HB; Li, T; Li, ZC; Li, ZL; Liu, R; Xiang, DD; Yin, HN; Zhu, ZM, 2011) |
| "Our results suggest that Cancer of the Liver Italian Program scores or Okuda stages, along with performance status, can be useful in stratifying patients with advanced HCC treated with sorafenib." | ( Baek, KK; Kang, WK; Kim, JH; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Uhm, JE, 2011) |
| "The failure of existing treatments for liver cancer has recently been attributed to the existence of cancer stem cells, which are difficult to kill using current drugs due to their chemoresistant properties as well as their ability to stimulate neoangiogenesis." | ( Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2011) |
| "Mesenchymal liver cancer post-EMT demonstrates TISC characteristics such as tumor-sphere formation but are not resistant to cytotoxic therapy." | ( Dang, H; Ding, W; Emerson, D; Rountree, CB, 2011) |
| "We report on five patients with liver cancer, not suitable for conventional therapies, treated with hepatic intra-arterial administration of fotemustine in combination with IFNα2b." | ( Arcoria, D; Calì, S; DI Maggio, EM; Ferraù, F; Malaponte, E; Panebianco, V; Parisi, A; Romeo, P; Vasta, F; Vitale, FV, 2011) |
| "Discussion Refractory biliary tract and hepatocellular cancers are difficult to treat, and no chemotherapy or biologically targeted therapies have impacted survival." | ( Bufill, JA; Chiorean, EG; Coleman, N; Currie, C; Johnston, EL; Loehrer, PJ; Picus, J; Ramasubbaiah, R; Tong, Y; Yu, M, 2012) |
| "According to the Korean Liver Cancer Study Group (KLCSG) practice guidelines, radiation therapy is considered appropriate for unresectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B, and tumors occupying less than two thirds of the liver with level II evidence." | ( Lee, IJ; Seong, J, 2011) |
| "According to Barcelona Clinic Liver Cancer (BCLC) staging, the curative treatment group included early stage HCC (BCLC-A), and the noncurative treatment group consisted of intermediate and advanced stages of HCC (BCLC-B, C)." | ( Choi, JY, 2011) |
| "Similarly, treatment of liver cancer cell lines HepG2 and Huh7, colon cancer cell line RKO, and breast cancer cell line MCF-7 with SAMe or its metabolite 5'-methylthioadenosine (MTA) reduced only Ubc9 protein level." | ( Giordano, P; Lu, SC; Mato, JM; Pascale, RM; Ramani, K; Tomasi, I; Tomasi, ML; Xu, J, 2012) |
| "Considering the high incidence of hepatic cancer and limited therapeutic approaches for treating this disease, it is important to develop liver cancer-specific chemopreventive agents." | ( Ahn, B; Kim, DJ; Kim, TM; Kim, TW; Shin, SK; Youm, SY, 2012) |
| "Seventeen patients with intrahepatic cancer undergoing focal radiation therapy (RT) were enrolled in institution review board-approved prospective studies to obtain DCE-MRI (to measure regional perfusion) and indocyanine green (ICG) clearance rates (to measure overall liver function) prior to, during, and at 1 and 2 months after treatment." | ( Balter, JM; Ben-Josef, E; Cao, Y; Feng, M; Hussain, H; Johnson, TD; Lawrence, TS; Normolle, D; Pan, C; Ten Haken, RK; Wang, H, 2013) |
| "Advanced hepatocellular cancer (HCC) is an incurable disease with limited options for systemic treatment." | ( Byrne, M; Estfan, B; Kim, R, 2013) |
| "The levels of liver cancer markers, including α-fetoprotein and carcinoembryonic antigen, were substantially increased by NDEA treatment." | ( Fareed, S; Hussain, T; Rao, CV; Siddiqui, HH; Vijayakumar, M, 2012) |
| "Treatment of Hep3B, human liver cancer cells, with the prodrug 5-fluorocytosine (5-FC) in the presence of HB1." | ( Choi, KC; Hwang, KA; Jeung, EB; Kang, NH; Kim, HC; Kim, SU; Yi, BR, 2012) |
| "Thirty advanced-stage liver cancer cases (primary and metastatic) treated with RE over a 3-year period were included." | ( Carpizo, DR; Foran, DJ; Gendel, VM; Gensure, RH; Jabbour, SK; Lee, VM; Nosher, JL; Yang, L, 2012) |
| "Using liver cancer-derived cell lines, we specifically show that the IRE1 and phosphorylated extracellular signal-regulated kinase arms of the unfolded protein response (UPR) become activated upon sorafenib treatment, whereas the ATF6 arm is inhibited." | ( Arma, D; Balabaud, C; Bexiga, MG; Bioulac-Sage, P; Blanc, JF; Castain, C; Chevet, E; Higa, A; Le Bail, B; Marza, E; Rosenbaum, J; Simpson, JC; Taouji, S; Yi, P, 2012) |
| "For recurrence of hepatocellular cancer after hepatic resection or local ablative therapy, compared with controls, participants receiving Vitamin K2, pooled relative risks for hepatocellular cancer were 0." | ( Amir, M; Badshah, MB; Kazi, AN; Rahman, S; Riaz, H; Riaz, IB; Riaz, T, 2012) |
| "The heterogeneity of liver cancer, in particular hepatocellular carcinoma (HCC), portrays the requirement of multiple targets for both its treatment and prevention." | ( Cao, M; Nelson, D; Prima, V; Svetlov, S, 2013) |
| "The multi-targeted therapy for liver cancer has been considered as a novel strategy to fight hepatocellular carcinoma." | ( Dong, X; Jiang, Y; Jin, HW; Li, N; Ma, ZZ; Tu, PF; Zeng, KW, 2013) |
| "The nude mouse model of human liver cancer was made by transplantation of human highly metastatic liver cancer cell line HCCLM3 cells, and the tumor-bearing nude mice were treated with sorafenib, 5-Fu or both, respectively, and mock-treated tumor-bearing nude mice as negative control." | ( Shen, HJ; Wang, YH; Xu, J, 2013) |
| "According to the Barcelona Clinic Liver Cancer (BCLC) algorithm, patients with advanced stage (BCLC-C) hepatocellular carcinoma (HCC) are recommended for systemic treatment or palliative therapy." | ( Blaszkowsky, LS; Ganguli, S; Kalva, SP; Liu, R; Pectasides, M; Rachamreddy, N; Surakanti, S; Wicky, S; Yeddula, K; Zhu, AX, 2014) |
| "The prognosis for patients with hepatocellular cancer (HCC) undergoing transarterial therapy (TACE/TAE) is variable." | ( Benini, R; Burroughs, AK; Fox, R; Hackshaw, A; Johnson, P; Kadalayil, L; Marelli, L; Meyer, T; O'Beirne, J; Pallan, L; Palmer, DH; Yu, D, 2013) |
| "Primary liver cancer has one of the highest mortality rates of all cancers, and the main current treatments have a poor prognosis." | ( Li, B; Liu, S; Pan, Y; Wu, H; Yin, H; Zhang, Y; Zhou, X, 2014) |
| "APE1 overexpression observed in hepatic cancer cells may reflect an adaptive response to cell damage and may be responsible for further cell resistance to chemotherapy and for the onset of inflammatory response." | ( Cesaratto, L; Codarin, E; Kelley, MR; Leonardi, A; Tell, G; Tiribelli, C; Vascotto, C, 2013) |
| "Induction of hepatic cancer was confirmed after 7 days of DENA administration by measurement of elevated level of serum α-feto protein (AFP)." | ( Ahmad, K; Ahmad, P; Al-Harbi, NO; Alam, MJ; Imam, F; Iqbal, M; Khusroo, MJ; Rahman, RU; Saleem, S; Shaharyar, MA, 2013) |
| "The IPS cells of liver cancer patients can be established effectively from fibrocytes and can be cultured stably in vitro, which provides an approach for the treatment of intermediate or advanced stage liver cancer." | ( Hu, JT; Li, JJ; Yan, P; Zhang, DM, 2014) |
| "Treatment of PC3 prostate and HepG2 liver cancer cells with compound 8." | ( Casey, PJ; Go, ML; Guo, D; Lau, HY; Ramanujulu, PM; Wang, M; Wirawan, M; Yang, T, 2014) |
| "According to the Barcelona Clinic Liver Cancer (BCLC) algorithm, intermediate-stage HCC is defined as extensive multifocal disease without vascular invasion in patients with preserved liver function and absence of cancer-related symptoms; in this context, transarterial chemoembolization (TACE) is considered the standard treatment." | ( Bruix, J; Forner, A; Gilabert, M; Raoul, JL, 2014) |
| "The Barcelona Clinic Liver Cancer (BCLC) system is the preferred staging system to evaluate patients with HCC and links prognosis assessment with treatment recommendation." | ( Alencar, RS; Alvares-da-Silva, MR; Alves, VA; Campos, PB; Carrilho, FJ; Chagas, AL; Diniz, MA; Kikuchi, L; Oliveira, CP; Ratziu, V; Santos, GR; Stefano, JT; Tani, CM; Vezozzo, DC, 2016) |
| "Patients with advanced hepatic cancer who underwent liver transplant and subsequent therapy between March 2007 and March 2009 in our hospital were selected for this study." | ( Fan, H; Gu, L; Jin, W; Kan, L; Shan, C; Wang, X, 2015) |
| "Currently, the Korean Liver Cancer Study Group and National Comprehensive Cancer Network guidelines recommend combined radiotherapy (RT) and chemotherapy for some selected cases." | ( Seong, J; Yoon, HI, 2014) |
| "Our study included 78 liver cancer patients who were treated with Y-90 radioembolization." | ( Aydin, F; Boz, A; Bozcuk, H; Coşkun, HS; Erkilic, M; Gunduz, S; Karayalçin, B; Ozdogan, M; Ozgur, O; Savas, B; Sindel, T; Yldlzs, A; Ylmaz, S, 2014) |
| "The morbidity and mortality rate of liver cancer continues to rise in China and advanced cases respond poorly to chemotherapy." | ( Guo, YL; Kong, QS; Liu, HS; Tan, WB, 2014) |
| "This study opens a new direction for liver cancer treatment." | ( Do, MS; Doan, CC; Doan, NT; Le, VD; Nguyen, MH; Nguyen, QH, 2015) |
| "Unresectable liver cancer presents a major problem in the treatment of solid tumors." | ( Mahnken, AH, 2015) |
| "Treatment of human liver cancer cell lines with FFAs exacerbated the EMT phenotype, whereas chemical inhibition of CD36 mitigated these effects." | ( Chan, C; Li, I; Nath, A; Roberts, LR, 2015) |
| "Human liver cancer HepG2 cell were treated with 10, 20, 30 and 40 µM xanthohumol for 48 h." | ( Huang, X; Jiang, K; Liang, B; Zhao, X, 2016) |
| "The Barcelona clinical liver cancer (BCLC) score endorsed by the European Society of the Liver EASL divides patients into five prognostic categories, each with a distinct treatment indication." | ( Colombo, M; Sangiovanni, A, 2016) |
| "MSFCs, CD90+ liver cancer cells (CD90+ LCCs), and parental MHCC97H cells were treated with no drug, LY294002 alone, 5-FU alone, or both drugs together and then compared in terms of stem cell-related gene expression, proliferation, and invasion." | ( Li, LQ; Lu, SD; Peng, NF; Peng, YC; Xie, ZB; You, XM; Zhong, JH, 2016) |
| "A promising strategy for liver cancer treatment is to deliver chemotherapeutic agents with multifunctional carriers into the tumor tissue via intra-arterial (IA) transcatheter infusion." | ( Chung, JW; Gordon, AC; Jeon, MJ; Kim, DH; Kim, YI; Larson, AC, 2016) |
| "To enhance locoregional therapies for liver cancer treatment, we propose in this study a mathematical model to optimize the transcatheter arterial delivery of therapeutical agents." | ( Belharet, K; Ferreira, A; Folio, D; Mellal, L, 2016) |
| "Using in vivo and in vitro models of liver cancer, we demonstrate that an increase in the level of p53 protein in nuclei, a decrease in the level of cytoplasmic p53, and, consequently, an increase in the ratio of nuclear/cytoplasmic p53 in rat preneoplastic livers and in rat and human HCC cell lines caused by tributyrin or sodium butyrate treatments was associated with a marked increase in the level of nuclear chromosome region maintenance 1 (CRM1) protein." | ( Beland, FA; de Conti, A; Fernandes, LH; Furtado, KS; Heidor, R; Horst, MA; Moreno, FS; Ortega, JF; Pogribna, M; Pogribny, IP; Shpyleva, S; Tavares, PE; Tryndyak, V, 2016) |
| "The Barcelona Clinic Liver Cancer (BCLC) staging system for hepatocellular carcinoma (HCC) recommends transarterial chemoembolization (TACE) as the first line therapy for stage B patients and sorafenib treatment for stage C patients." | ( Achakzai, R; Gou, CY; Li, JY; Li, L; Li, XH, 2016) |
| "Since the liver cancer cells have a strong capacity to repair irradiative injury, new medicines to enhance this treatment are urgently required." | ( Cheng, X; Feng, Z; Jiang, X; Liu, X; Wang, Q; Yang, C; Zhang, Y; Zhou, P, 2016) |
| "causes apoptosis of liver cancer cells through ER stress pathway, which supports the ethnomedicinal use of this herb as an alternative or complementary therapy for cancer." | ( Lee, SC; Liu, N; Lu, YC; Wang, L; Wang, P; Yang, HL; Yang, YJ, 2016) |
| "Surgery is the main treatment for liver cancer, but the most common liver cancer – called hepatocellular carcinoma – can sometimes become too large to remove safely." | ( Chao, M; Hu, X; Jin, K; Li, B; Wu, H; Wu, J; Yang, G; Zhang, G, 2016) |
| "Incubation of liver cancer cells with TLCL significantly restored apoptotic sensitivity accompanied by an increase of CL and its oxidation products when treated with staurosporine (STS) or Sorafenib (the standard treatment for late stage HCC patients)." | ( Chen, Q; Cheng, S; Lu, J; Sa, R; Tao, Y; Waeg, G; Xia, L; Xiao, M; Yin, H; Zarkovic, K; Zarkovic, N; Zhong, H; Zhu, M, 2017) |
| "The antitumor effect in mice liver cancer cells (H22) in tumor-bearing Kunming (KM) mice demonstrated that this nanocarrier exhibits high therapeutic efficiency in artificial solid tumors and low toxicity to normal tissues, with a survival rate of approximately 100% after 160 days of treatment." | ( Wang, Y; Wei, X; Xiong, X; Zhang, L; Zhang, X; Zhou, S, 2017) |
| "However, the effects of BA treatment on liver cancer have little to be known." | ( Feng, YL; Li, J; Li, QJ; Pan, F; Xu, Y, 2017) |
| "Human liver cancer cell strain SMMC-7721 was cultured and treated with different curcumin concentrations for different times followed by measuring the changes of cell proliferation activity and cycle by MTT and flow cytometry, respectively." | ( Fang, ZY; Li, D; Liu, JS; Xiang, H; Zhang, H; Zhang, YJ, 2017) |
| "The number of human liver cancer SMMC-7721 cells increased in G1 stage and decreased in S stage after treated with different concentrations of curcumin." | ( Fang, ZY; Li, D; Liu, JS; Xiang, H; Zhang, H; Zhang, YJ, 2017) |
| "Barcelona clinic liver cancer-stage C (BCLC-C) encompasses a broad spectrum of tumor burdens, liver function statuses, patient prognoses, and treatment strategies." | ( Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, HJ; Kim, HS; Park, CH; Rew, JS; Shin, SS; Yoon, JH, 2017) |
| "Determining the origin of liver cancer stem cells is important for treating hepatocellular carcinoma." | ( Bian, Z; Chen, C; Dai, B; Huang, Q; Liu, W; Pu, M; Qu, X; Shen, L; Tang, H; Tao, K; Zhao, G, 2017) |
| "Examination of liver cancer in diethylnitrosamine (DEN)-treated CUGBP1-S302A mice showed these mice develop much more severe liver cancer that is associated with elimination of the mutant CUGBP1." | ( Cast, A; Iakova, P; Karns, R; Lewis, K; Stock, L; Timchenko, L; Timchenko, N; Valanejad, L; Wei, C; Wright, M, 2017) |
| "Traditional chemotherapy for liver cancer has big side effects for patients, whereas targeted drugs, such as sorafenib, commonly have drug resistance." | ( Dai, Y; Guo, Q; He, Z; Wei, L; Yang, L; Yao, J; Zhao, L; Zhou, Y, 2017) |
| "Various liver cancer cell lines were treated with either sorafenib only or with sorafenib after infection of adenovirus expressing short hairpin RNA (shRNA) against transforming growth factor-β (TGF-β) and p38 activity was examined using western blotting." | ( Choi, HJ; Han, Z; Joo, Y; Kang, D; Oh, GH; Song, JJ, 2017) |
| "Treating liver cancer cells with antioxidant N-acetyl cystein (NAC) partly blocked AGEs-induced ChREBP expression and cell proliferation." | ( Chen, H; Ding, W; Li, M; Li, Y; Lin, N; Meng, J; Su, Q; Tong, X; Wu, L; Yang, D; Zhu, Y, 2017) |
| "High mortality rates in ovarian and liver cancer are largely a result of resistance to currently used chemotherapy." | ( Bukowska, B; Marczak, A; Rogalska, A, 2018) |
| "Treatment of the liver cancer stem cells with mefloquine markedly decreased the potential to undergo self-renewal at 10 μM concentration after 48 h." | ( Gong, LL; Li, YH; Lin, RX; Wu, JC; Yang, SL; Zhang, GF, 2018) |
| "We also report that the liver cancer patients non-responding to sorafenib treatment exhibit higher expression of SULF2 and LCN2." | ( Bae, MH; Choi, JH; Chung, T; Im, JY; Kim, DY; Kim, HC; Kim, HH; Kwon, JH; Lee, EJ; Park, YN; Wang, HJ; Woo, HG; Yoon, S, 2018) |
| "Forty-nine patients with liver cancer who received drug-eluting beads transarterial chemoembolization treatment were consecutively enrolled in this cohort study." | ( Chen, R; Hu, H; Wu, X; Zheng, W, 2018) |
| "Treatment of liver cancer remains challenging because of a paucity of drugs that target critical dependencies." | ( Beijersbergen, RL; Bernards, R; Evers, B; Gao, D; Jin, G; Jin, H; Lieftink, C; Qin, W; Wang, C; Wang, L; Xue, Z, 2018) |
| "Our results provide novel insight into liver cancer therapy." | ( Chen, X; Li, X; Lv, H; Shang, P; Shen, Y; Wang, S; Xue, Y; Yang, J; Zhao, B, 2018) |
| "In this study, patients with liver cancer exhibited reduced VM in tumor tissues after treatment with Rhizoma Paridis." | ( Chen, S; Lei, Y; Liang, Y; Liu, H; Liu, Y; Meng, J; Qian, B; Qiao, K; Sun, T; Wang, H; Xiao, T; Yang, C; Zhang, H; Zhao, J; Zhong, W; Zhou, H; Zong, S, 2018) |
| "Barcelona Clinic Liver Cancer (BCLC) C patients with nonsegmental shunts who received lobar administrations had a grade ≥3 AE rate of 38% compared with the remaining cohort, which was 12% (P = ." | ( Geller, BS; Kapp, M; Pepin, EW; Shah, JL; Thornton, LM; Toskich, BB, 2018) |
| "Herein, we show in 2 different liver cancer models that myeloid-derived suppressor cells are increased in response to cytokine-induced killer cell therapy." | ( Agdashian, D; Brown, ZJ; Fu, Q; Greten, TF; Heinrich, B; Korangy, F; Ma, C; Rosato, U; Sandhu, M; Yu, SJ; Zhang, Q, 2019) |
| "In this study, sera samples, staged hepatic cancer tissues from Sor-treated patients with advanced HCC were harvested for a group of biochemical tests and immunoassays." | ( Liu, M; Su, M; Wu, X; Xu, X; Yang, B; Zhou, R, 2018) |
| "The treatment of liver cancer includes surgery and medication, of which, the former is more effective." | ( Cui, H; Cui, X; Jin, W; Jin, Y; Shen, X; Sun, H, 2019) |
| "The metastasis of liver cancer is a major cause of clinical treatment failure, restrain, and control the cancer metastasis is the major strategy of the treatment and prevention of the disease." | ( Ding, Y; Guo, H; Kong, D; Pang, D; Xu, C, 2018) |
| "Advanced liver cancer often exhibits a poor response to chemotherapy and poor prognosis due to acquired chemoresistance and tumor recurrence." | ( Deng, F; Hu, JQ; Hu, XP; Tian, XF; Zeng, XC; Zhang, W, 2018) |
| "The most effective way of treating liver cancer is surgical resection, which usually requires blocking the hepatic portal circulation, and may result in hepatic ischemia-reperfusion injury (HIRI)." | ( Gao, Y; Huang, JH; Huo, X; Lv, Y; Qi, D; Sheng, S; Wang, F; Wu, E; Zhou, S; Zhou, Y, 2018) |
| "Ex vivo cultured liver cancer tissues from a patient were treated with vismodegib as a single‑agent or in combination with entinostat, and analyzed by histological and immunohistochemical methods." | ( Cai, H; Li, H; Li, J; Liu, Y; Shi, Y; Song, H; Sun, Y; Wang, D; Wang, Y, 2019) |
| "Thus, after treatment of liver cancer cell line HepG-2 with 50 μM of each compound, cell viability was determined." | ( Badria, FA; El-Senduny, FF; Youssef, MM; Zidane, MM, 2019) |
| "Gene therapy strategies for liver cancer have broad application prospects but still lack a stable and efficient delivery vehicle." | ( Dong, S; Lee, RJ; Liu, L; Lu, J; Meng, Q; Teng, L; Xie, J; Yao, Y; Zhang, J; Zhang, Y; Zhao, Y, 2019) |
| "Malignancies treated included hepatocellular cancer (n = 14; 30%), colorectal cancer (n = 11; 23%), cholangiocarcinoma (n = 8; 17%), neuroendocrine (n = 8; 17%) and other tumors (n = 6)." | ( Abbott, DE; Alseidi, A; Bentrem, DJ; Borel Rinkes, IHM; Chadalavada, S; Choi, GH; Dhar, VK; Eng, OS; Fisher, AV; Fong, Y; Hagendoorn, J; Johnson, AC; Kies, D; Latorre, K; Lewandowski, R; Maithel, SK; Makris, E; Melstrom, LG; Poultsides, G; Raoof, M; Rocha, F; Ronnekleiv-Kelly, S; Salem, R; Sekhar, A; Shah, SA; Singh, G; Weber, SM; Winslow, ER, 2019) |
| "The CP classification, Barcelona Clinic Liver Cancer staging system, and treatment modality might predict mortality in patients with HCC." | ( Gani, RA; Hasan, I; Jasirwan, COM; Kalista, KF; Kurniawan, J; Lesmana, CRA; Nababan, SH; Sulaiman, AS, 2020) |
| "Stimulating ferroptosis in liver cancer cells is a strategy to treat liver cancer." | ( Bian, Z; Chen, Y; Liu, Y; Pan, Q; Sun, F; Wu, Q; Zhang, X; Zhang, Y; Zhu, G, 2019) |
| "Animal studies in liver cancer xenograft model demonstrated significant suppression of tumor burden, reduced tumor cell and elevated TUNEL positive apoptosis with no toxicity concerns in animals treated with G-S27LN formulation." | ( Duan, X; Wang, Z; Zhang, Y; Zhao, K; Zhao, Y, 2019) |
| "Briefly, liver cancer cells were treated with muscone and the rates of cellular apoptosis and autophagy were investigated using staining techniques and western blotting." | ( Jiangshan Dai, J; Li, Z; Qi, W; Wang, D; Wu, C; Xia, L; Xu, S; Yang, C; Zhang, Q, 2020) |
| "Targeting AMPK and lipid metabolism of hepatocellular cancer stem cells is a promising strategy to face stemness and chemotherapy resistance." | ( Bort, A; de Miguel, I; Diaz-Laviada, I; Mateos-Gómez, PA; Sánchez, BG, 2020) |
| "The Barcelona Clinic Liver Cancer (BCLC) stages following downsizing after prior treatment were A, B and C in 17, 22 and 30 patients, respectively." | ( Ando, S; Fuchigami, A; Fujii, Y; Imai, Y; Mochida, S; Nakayama, N; Nakazawa, M; Sugawara, K; Tomiya, T; Uchida, Y; Uchiya, H, 2020) |
| "Thirteen liver cancer cell lines were cultured followed by treatment with varying concentrations of quercetin (0-100 μM) or quercetin and 5-FU, and the cell viability was analysed by the MTT assay." | ( Akagi, Y; Akiba, J; Fujita, F; Fukutomi, S; Goto, Y; Hisaka, T; Mizobe, T; Naito, Y; Nakashima, K; Nakashima, O; Nomura, Y; Ogasawara, S; Okuda, K; Sakai, H; Sato, T; Tanigawa, M; Yano, H, 2020) |
| "Treatment of liver cancer with conventional method bears several side effects, thus to undertake these side effects as a formulation challenge, it is necessary to develop novel target-specific drug delivery system for the effective and better localization of drug into the proximity of target with restricting the movement of the drug in normal tissues." | ( Jain, AK; Mishra, K; Sahu, H; Thareja, S, 2021) |
| "According to Barcelona Clinic Liver Cancer classification, transarterial chemoembolization (TACE) is preferred treatment for stage B and in certain cases for stage A hepatocellular carcinoma (HCC)." | ( Dimov, V; Dimova, B; Gjoreski, A; Grozdanovska Angelovska, B; Jovanoska, I; Mitrevski, N; Nedelkovski, D; Popova Jovanovska, R; Prgova Veljanova, B; Risteski, F, 2021) |
| "The Barcelona Clinic Liver Cancer criteria used to guide treatment considers performance status and assessment of liver function by Child-Pugh score in addition to tumor size and location." | ( Draper, A, 2020) |
| "The remaining 10 rats were the liver cancer model group and treated with diethylnitrosamine (DEN) to induce liver cancer." | ( Bai, MJ; Bu, JG; Chen, CY; Li, JQ; Liu, ZH; Yan, SH; Ye, XW, 2021) |
| "The Hep-G2 and SMMC-7721 liver cancer cell lines were treated with phenformin and Ku either alone or in combination, after which the impact of these drugs on cellular proliferation was assessed via 3-(4,5-dimethylthiazol) 2, 5-diphenyltetrazolium and colony formation assays, whereas Transwell assays were used to gauge cell migratory activity." | ( Deng, J; Hu, X; Huang, L; Huang, M; Li, G; Qin, M; Tang, J; Wu, J; Wu, T; Xiao, D; Yan, X; Yang, X; Zhou, S, 2021) |
| "Advanced stage liver cancer is predominantly treated with the multi-kinase inhibitor sorafenib; however, this therapeutic agent lacks selectivity in its cytotoxic actions and is associated with poor survival outcomes." | ( Andrewartha, N; Buyan, A; Corry, B; Nutt, MJ; Stewart, SG; Yee, YS; Yeoh, GCT, 2021) |
| "Ozone treatment inhibited liver cancer cell proliferation, colony formation." | ( He, X; Huang, Q; Li, J; Li, X; Tang, S; Zeng, T; Zhong, M, 2021) |
| "The fact that the three liver cancer cell lines responded differently, yet positively, to CDDP + APG cotreatment could be attributed to variations they present in gene expression." | ( Anninou, N; Koukoulis, G; Papachristou, F; Paraskakis, S; Pitiakoudis, M; Sertaridou, E; Simopoulos, C; Tsalikidis, C; Tsaroucha, A, 2021) |
| "Consequently, we treated three primary liver cancer cell lines with two anthracyclins (doxorubicin and idarubin) and studied the changes in the lipidome." | ( Balgoma, D; Calitz, C; Hedeland, M; Heindryckx, F; Kopsida, M; Kullenberg, F; Lennernäs, H, 2021) |
| "Three patients with advanced liver cancer treated at our institution had very poor ICG retention rates during treatment with lenvatinib." | ( Aratake, Y; Furukawa, M; Hisano, T; Iguchi, T; Inada, H; Lee, L; Mano, Y; Matsumoto, Y; Miki, M; Nakanishi, A; Okumura, Y; Senju, T; Sugimachi, K; Sugimoto, R; Taguchi, K; Tanaka, Y, 2021) |
| "Treatment of liver cancer has always been a challenge for clinicians and development of appropriate drug against hepatocellular carcinoma is the major focus for researchers working in the field." | ( Ali, S; Inam, A; Rizwan, M; Younas, M; Zubair, M, 2021) |
| "Metformin upregulated glycolysis in liver cancer cells, thereby increasing sensitivity to the DCA treatment." | ( Cho, Y; Choi, DH; Kim, SY; Kim, TS; Lee, CY; Lee, M; Park, M; Shim, MS, 2021) |
| "We aimed at finding and verifying new liver cancer markers by combining informatics analysis with experimental exploration to provide new ideas and methods for the diagnosis and treatment of clinical liver cancer." | ( Bai, M; Bao, Y; Cui, M; Huang, Y; Li, Y; Song, Z; Sun, L; Sun, Y; Wang, G; Yu, C; Yu, Z; Zheng, L, 2021) |
| "In the present study, hepatocellular cancer (HCC) induced by diethylnitrosamine (DEN) in rats and then treated with the new chromene derivative and the parameters TNF-α, VEGF, p53, Cyt C, MMP-9, Bcl2, and Bax were measured." | ( El-Mezayen, HA; Mahdy, EME; Mansour, SZ; Mohamed, SA; Nabeel, AI, 2022) |
| "NRG's efficiency in treating hepatic cancer was increased by using SLN's approach." | ( Kang, Q; Liang, X; Liu, Q; Wang, W; Wang, Z, 2022) |
| "HCC is one of the main types of primary liver cancer, with high morbidity and mortality and poor treatment effect." | ( Cheng, X; Guo, Z; He, M; Huang, L; Liu, Z; Lu, X; Ma, T; Peng, W; Tang, F; Tian, S; Tu, F; Wang, X; Wu, Y; Xu, X; Yang, J; Ye, J; Zeng, X; Zhang, L; Zhang, P; Zou, J, 2022) |
| "Careful treatment of both RHF and liver cancer might be necessary for patients with RHF with primary or metastatic liver cancer." | ( Doi, H; Hashi, K; Hishikawa, D; Ikegami, T; Inui, A; Kage, M; Kanto, T; Kawai, H; Komatsu, H; Kusano, H; Matsuda, M; Mori, T; Okawara, M; Okuzaki, D; Osawa, Y; Oyama, C; Sakamoto, Y; Shimagaki, T; Shindou, H; Sugiyama, M; Tamura-Nakano, M; Tsunoda, T; Tsutsui, Y; Yamazoe, T; Yanaga, K; Yanagida, K; Yoshida, Y; Yoshikawa, S; Yoshio, S, 2022) |
| "In parallel to the incidence of hepatic cancer, we found lung, heart, and kidney cancer after treatment with DEN." | ( Abdelhafez, MA; Darwish, AM; Mahrous, KF; Zoheir, KMA, 2022) |
| "Current treatments to combat liver cancer are limited." | ( Cheng, WC; Chu, YC; Lin, CC; Lin, SC; Lin, YC; Lu, IT; Sheu, JH; Wen, Y, 2022) |
| "Despite the increasing occurrence of liver cancer, it has a poor prognosis and potential treatment options are still lacking." | ( Chen, X; Dong, P; Huang, Z; Liu, H; Zeng, X, 2022) |
| "As the most common pediatric primary liver cancer with rising incidence, hepatoblastoma remains challenging to treat." | ( Rangaswami, A; Wu, PV, 2022) |
| "The presence of liver cancer stem cells (LCSCs) is one of the reasons for the treatment failure of hepatocellular carcinoma (HCC)." | ( Chen, Y; Chen, Z; Fan, J; Fan, X; Li, L; Shi, Y; Tian, R; Wang, H; Yang, X; Zhang, J; Zhang, K, 2022) |
| "The Barcelona Clinic Liver Cancer (BCLC) classification is the most widely used staging system in management of HCC that helps allocate treatments." | ( Goyal, P; Mouli, SK; Salem, R, 2022) |
| "Poor diagnosis of primary liver cancer and limited treatment strategies aggravate the challenges." | ( Ahmad, A; Ahmad, I; Alabdallah, NM; Ansari, IA; Ashfaque, M; Bajpai, P; Mishra, A; Saeed, M; Shekh, R; Tiwari, RK, 2022) |
| "Barcelona Clinic Liver Cancer stages at treatment were A (13%), B (33%), C (52%), and D (2%)." | ( Al-Omary, A; Chan, C; Chan, MV; Chang, J; Cheng, R; Clark-Dickson, M; Danta, M; Davison, SA; Gupta, S; Hillhouse, JW; Huo, YR; Jebeili, H; Laube, R; Lee, AU; Levy, MT; Liu, K; Lockart, I; Nguyen, V; Prince, DS; Rogan, C; Schlaphoff, G; Strasser, SI; Thailakanathan, C; Tiwari, N; Xiang, H; Zekry, A, 2022) |
| "Although many treatments for liver cancer have been studied, the prognosis for liver cancer is still very poor." | ( Bai, X; Li, X; Peng, X; Qiao, C; Tang, Y; Zhao, R, 2023) |
| "Although many treatments for liver cancer have been studied, the prognosis for liver cancer is still very poor." | ( Bai, X; Li, X; Peng, X; Qiao, C; Tang, Y; Zhao, R, 2023) |
| "Although many treatments for liver cancer have been studied, the prognosis for liver cancer is still very poor." | ( Bai, X; Li, X; Peng, X; Qiao, C; Tang, Y; Zhao, R, 2023) |
| "The Chinese liver cancer (CNLC) staging system proposed in the 2017 guidelines continues to be the standard model for staging with modifications in the treatment allocations." | ( Fan, J; Gao, Q; Shi, J; Xie, D; Zhou, J, 2023) |
| "Eighty patients with liver cancer and cirrhosis undergoing elective LH were randomized into ulinastatin (administered immediately before hepatectomy) group, dexmedetomidine (administered before anesthesia induction) group, ulinastatin plus dexmedetomidine group, and saline group (groups U, D, UD, and C, respectively)." | ( Liu, G; Ou, Y; Yang, Y; Yin, F; Zhang, F, 2022) |
| "si‑PTBP1 introduction into SF‑treated liver cancer cells resulted in a significant reduction in the levels of MDA and iron." | ( Bi, T; Li, J; Liu, Z; Sun, W; Wang, Q; Wang, W; Xu, Y; Yang, H, 2023) |
| "To detect and treat liver cancers, it is imperative to study how HClO levels change in hepatocytes." | ( Cheng, D; He, L; Li, S; Liu, Y; Wang, P; Yang, K, 2023) |
| "HIGD2A promoted liver cancer cell growth by fueling mitochondrial ATP synthesis and activating the MAPK/ERK pathway, suggested that targeting HIGD2A may represent a new strategy for HCC therapy." | ( Chen, Y; Huang, K; Li, C; Li, X; Lin, Z; Liu, H; Liu, Z; Wang, Y; Xie, Z; Zhang, H; Zhang, X, 2023) |
| "TEM showed that lysionotin-treated liver cancer cells showed an extensively distended and dilated endoplasmic reticulum lumen." | ( Gao, Y; Li, D; Li, M; Lin, H; Shi, H; Wang, G; Wang, X; Yi, F; Yin, Y; Zou, Y, 2023) |
| "The 2022 Barcelona Clinic Liver Cancer (BCLC) guidelines incorporate a new section on clinical decision-making for personalized medicine, although the first treatment suggested by the BCLC guidelines is based on solid scientific evidence." | ( Irizato, M; Marugami, N; Minamiguchi, K; Nishiofuku, H; Taiji, R; Tanaka, T; Uchiyama, T, 2023) |
| "The treatment of liver cancer meets significant challenges in the high recurrence rate and invasive incidence." | ( Chen, F; Deng, ZY; Hong, H; Hu, QR; Huang, QX; Li, J; Luo, T; Pan, Y, 2023) |
| "The Huh-7 liver cancer cells and the H22 tumor-bearing mice were treated with Rh2 and Rh2-O." | ( Chen, F; Deng, ZY; Hong, H; Hu, QR; Huang, QX; Li, J; Luo, T; Pan, Y, 2023) |